PMID- 24260730
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20131122
LR  - 20211021
IS  - 2233-8276 (Print)
IS  - 2233-8268 (Electronic)
IS  - 2233-8276 (Linking)
VI  - 3
IP  - 4
DP  - 2013 Oct
TI  - Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective 
      study.
PG  - 249-56
LID - 10.5415/apallergy.2013.3.4.249 [doi]
AB  - BACKGROUND: Intravenous immunoglobulin (IVIG) is a biological product with 
      adverse effects that appears to vary considerably among different IVIG 
      preparations. OBJECTIVES: To describe the adverse events of patients given 
      intravenous immunoglobulin infusions. METHOD: Data was collected on all patients 
      receiving IVIG infusion at a tertiary hospital from January 2001 to December 
      2010. Descriptive statistics was used. RESULTS: 77 patients (45 males, 32 
      females) received IVIG infusions. Thirty two percent (n = 25) experienced adverse 
      reactions. The most common indication was Kawasaki disease (85.7%) followed by 
      immunodeficiency disorders (7.8%). Majority of the patients were children, with 
      the highest frequency of infusions among those aged 2 to 8 years old (52%). 36 
      infusions were associated with occurrence of adverse effects. Fever was the most 
      common adverse event (n = 11, 30.6%), followed by rash (n = 8, 22.2%) and chills 
      (n = 7, 19.4%). Other adverse events were cyanosis (n = 3, 8.3%), hypotension (n 
      = 2, 5.6%), hypothermia (n = 2, 5.6%), irritability (n = 1, 2.8%), vomiting (n = 
      1, 2.8%), and chest pain (n = 1, 2.8%). Adverse events were observed to occur 
      most frequently within 1 to 6 h from onset of IVIG infusion. Among the various 
      IVIG preparations available locally (Gammagard, Kiovig, Gamimune, Veno-S & IV 
      Globulin S), Gammagard was the brand frequently used (50.7%). It also has the 
      most number of adverse events, with 17 out of 41 (41.5%) infusions resulting in 
      adverse reactions. Most of the reactions occurred with fast infusion rates, and 
      clinical manifestations subsided when the rate of infusion was reduced. 
      CONCLUSION: In this study, thirty two percent of patients given IVIG infusions 
      experienced adverse events. Fever was the most common manifestation. Symptoms 
      occurred within 1 to 6 h from onset of infusion, were affected by fast infusion 
      rates, and managed by reducing the rate of infusion.
FAU - Palabrica, Frances Rose R
AU  - Palabrica FR
AD  - Allergy, Asthma and Immunology Unit, Dr. Fe del Mundo Medical Center, Quezon 
      City, Metro Manila 1100, Philippines.
FAU - Kwong, Shirley L
AU  - Kwong SL
FAU - Padua, Florecita R
AU  - Padua FR
LA  - eng
PT  - Journal Article
DEP - 20131031
PL  - Netherlands
TA  - Asia Pac Allergy
JT  - Asia Pacific allergy
JID - 101561954
PMC - PMC3826603
OTO - NOTNLM
OT  - Intravenous immunoglobulins
OT  - Retrospective study
OT  - Side effects
EDAT- 2013/11/22 06:00
MHDA- 2013/11/22 06:01
PMCR- 2013/10/01
CRDT- 2013/11/22 06:00
PHST- 2013/05/26 00:00 [received]
PHST- 2013/07/30 00:00 [accepted]
PHST- 2013/11/22 06:00 [entrez]
PHST- 2013/11/22 06:00 [pubmed]
PHST- 2013/11/22 06:01 [medline]
PHST- 2013/10/01 00:00 [pmc-release]
AID - 10.5415/apallergy.2013.3.4.249 [doi]
PST - ppublish
SO  - Asia Pac Allergy. 2013 Oct;3(4):249-56. doi: 10.5415/apallergy.2013.3.4.249. Epub 
      2013 Oct 31.